Emerging Strategies in Novel Targeted Therapies for Genitourinary Cancers (Prostate Cancer, Renal Cell Carcinoma and Urothelial Bladder Carcinoma)

This series is intended to improve care of patients with genitourinary cancers (Prostate Cancer, Renal Cell Carcinoma and Urothelial Bladder Carcinoma) by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus.

FACULTY

Hans Hammers, MD, PhD
Associate Professor
Department of Internal Medicine
The UT Southwestern Medical Center
Dallas, TX

Eric Jonasch, MD
Professor
Department of Genitourinary
  Medical Oncology
Division of Cancer Medicine
The University of Texas MD
  Anderson Cancer Center
Houston, TX

Ashish Kamat, MD
Professor
Department of Genitourinary
  Medical Oncology
Division of Cancer Medicine
The University of Texas MD
  Anderson Cancer Center
Houston, TX

Sumit Subudhi, MD, PhD
Assistant Professor
Department of Genitourinary
  Medical Oncology
Division of Cancer Medicine
The University of Texas MD
  Anderson Cancer Center
Houston, TX

Nizar M. Tannir, MD
Professor
Department of Genitourinary
  Medical Oncology
Division of Cancer Medicine
The University of Texas MD
  Anderson Cancer Center
Houston, TX

Amado Zurita, MD
Associate Professor
Department of Genitourinary
  Medical Oncology
Division of Cancer Medicine
The University of Texas MD
  Anderson Cancer Center
Houston, TX

Jointly provided by

These activities are supported by an educational grant from
Ferring Pharmaceuticals Inc. and Eisai, Inc.